BLOG

SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice – in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner

Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113)

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}